RESUMEN
Human immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of individuals in all age groups. The landscape of HIV infection has changed significantly in recent years due to the introduction of effective combination antiretroviral therapies (ART). A key component of first-line ART regimens for HIV treatment is abacavir, a nucleoside HIV reverse transcriptase inhibitor. Although abacavir is effective in suppressing viral replication and managing disease, its clinical utility is overshadowed by the potential for life-threatening hypersensitivity reactions in HLA-B*57:01-positive patients. In our country, local data obtained from various centers regarding the prevalence of HLA-B*57:01 in HIV-1-infected patients are available. In this study, it was aimed to determine the prevalence of the HLA-B*57:01 genotype in HIV-infected patients who were followed up and treated in many regions of our country. This retrospective study consists of the data of the patients aged 18 years and over diagnosed with HIV-1 infection between 01.01.2019 and 31.07.2022. Age, gender, place of birth, mode of transmission of the disease, death status, CD4+ T cell count and HIV RNA levels at the first clinical presentation, HLA-B*57:01 positivity, and the method used, clinical stage of the disease, virological response time with the treatment they received were recorded from the patient files. Data were collected from 16 centers and each center used different methods to detect HLA-B*57:01. These methods were sequence-specific oligonucleotide probe hybridization (SSOP), DNA sequence-based typing (SBT), single-specific primer-polymerase chain reaction (SSP-PCR), allele-specific PCR (AS-PCR) and quantitative PCR (Q-PCR). A total of 608 HIV-infected individuals, 523 males (86%) and 85 females (14%), were included in the study. The mean age of the patients was 36.9 ± 11.9 (18-73) years. The prevalence of HLA-B*57:01 allele was found to be 3.6% (22 patients). The number of CD4+ T lymphocytes in HLA-B*57:01 allele-positive patients was > 500/ mm3 in 10 patients (45.5%), while the number of CD4+ T lymphocytes in HLA-B*57:01 negative patients was > 500/mm3 in 216 patients (36.9%) (p> 0.05). Viral load at the time of diagnosis was found to be lower in patients with positive HLA-B*57:01 allele but it was not statistically significant (p> 0.05). Although different treatment algorithms were used in the centers following the patients, it was observed that the duration of virological response was shorter in HLA-B*57:01 positive patients (p= 0.006). Although the presence of the HLA-B*57:01 allele has a negative impact due to its association with hypersensitivity, it is likely to continue to attract interest due to its association with slower progression of HIV infection and reduced risk of developing AIDS. In addition, although the answer to the question of whether it is cost-effective to screen patients for HLA-B*57:01 before starting an abacavir-containing ART regimen for the treatment of HIV infection is being sought, it seems that HIV treatment guidelines will continue to recommend screening to identify patients at risk in this regard.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Ciclopropanos , Didesoxiadenosina/análogos & derivados , Infecciones por VIH , VIH-1 , Femenino , Masculino , Humanos , Adolescente , Adulto , Persona de Mediana Edad , Prevalencia , Calidad de Vida , Estudios Retrospectivos , Turquía , Antígenos HLARESUMEN
Long COVID is defined as symptoms related to various organs following COVID-19. There is currently very little information available about the prevalence of these symptoms and their long-term recovery time. The aim of this study was to describe the symptoms that persisted nine months after COVID-19. This cross-sectional study was conducted in Antalya, Türkiye, between November 1 and 30, 2020 on COVID-19 patients. Patients were contacted approximately nine months later by two infectious diseases physicians, and the questionnaire which included 27 symptoms was completed. Of the 390 patients who met the criteria, 329 agreed to participate in the study. Patients' average age was 48.9 ± 14.4 years, and 51.7% were male. 79.3% of the people still had at least one symptom at the end of the ninth month. The most common symptoms were weakness-fatigue (54.7%), forgetfulness (45.3%), effort loss (35.0%), sleep disturbance (34.3%), joint pain (27.4%), and hair loss (23.4%). According to analysis performed in terms of sex; hair loss, diarrhea, nausea, dizziness, sore throat, loss of taste and smell were more common in women than in men (p= 0.042, p= 0.047, p= 0.050, p= 0.026, p= 0.016, p= 0.036, p= 0.027, respectively). Individuals aged 65 years and over had a significantly lower number of symptoms (p= 0.029) than all other age groups. Furthermore, the number of symptoms was higher in patients who used steroids (p= 0.049). This study is an important source of information on the long-term symptoms of COVID-19. Our results have shown that the symptoms associated with COVID-19 do not completely resolve even after nine months, which explains why long COVID requires continuous monitoring.
Asunto(s)
COVID-19 , Infecciones por Coronavirus , Coronavirus , Humanos , Femenino , Masculino , Adulto , Persona de Mediana Edad , Estudios Transversales , Hospitales , Alopecia , Síndrome Post Agudo de COVID-19RESUMEN
OBJECTIVE: In recent years, there has been worldwide recognition of the problems associated with Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS). The prevalence of cardiovascular disease in the HIV-infected population is increasing. Repolarization abnormalities, the significant contributor to life-threatening arrhythmias and mortality, are the most frequent electrocardiographic changes in this population. This study aimed to evaluate the changes in Tp-e interval, Tp-e/QT and Tp-e/corrected QT (QTc) ratios, and traditional electrocardiographic features of electrical dispersion in adults infected with HIV. SUBJECTS AND METHODS: A total of 235 participants were selected in the current study. The HIV group consisted of 85 subjects (median age 36 years [25-48], and the control group included 150 individuals (median age 39 years [27-51]). Tp-e interval, Tp-e/QT and Tp-e/QTc ratios were measured by the 12-lead electrocardiogram. RESULTS: Tp-e interval, cTp-e interval, and Tp-e/QT and Tp-e/QTc ratios were significantly higher in HIV patients compared to the control group (p = 0.006, p = 0.004, p = 0.003, and p = 0.002, respectively). In correlation analysis, there was inverse correlation between the mean cTp-e interval and CD4 count and Tp-e/QTc ratios and CD4 count (r = - 0.407, p < 0.001, r = - 0.416, p < 0.001, respectively). Besides, there was correlation between the mean cTp-e interval and high-sensitivity C-reactive protein (hsCRP) and Tp-e/QTc ratios and hsCRP (r = 0.403, p = 0.001, r = 0.406, p = 0.001, respectively). CONCLUSION: Our study revealed that the cTp-e interval, Tp-e/QT and cTp-e/QT ratios were prolonged and correlated to the severity of the disease in HIV-infected patients. Our findings may shed light on the cTp-e interval and Tp-e/QTc ratio and lead to further studies showing a relationship with ventricular arrhythmias and mortality in HIV-infected individuals.
Asunto(s)
Arritmias Cardíacas/epidemiología , Arritmias Cardíacas/patología , Infecciones por VIH/epidemiología , Adulto , Factores de Edad , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores SexualesRESUMEN
INTRODUCTION: Single-tablet regimens (STRs) can increase treatment success and even improve the quality of life of human immunodeficiency virus (HIV) patients. In this study, we aim to analyze the real-life efficacy and tolerability data of people living with HIV (PLWH) initiated on or switched to bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) as first-line treatment. MATERIALS AND METHODS: This retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022. Patients who received BIC/FTC/TAF for at least 12 months were included in this study. Virological suppression, laboratory parameters, side effects, and immunological response were analyzed at one, three, six, nine, and 12 months. RESULTS: A total of 116 patients, 66 (56.9%) treatment-experienced and 50 (43.1%) naive, were evaluated within the scope of the study. In the naive patient group, baseline HIV-RNA, CD4+ and CD8+ T cell counts, CD4/CD8 ratio, and estimated glomerular filtration rate (eGFR) values were significantly different in different follow-up months. The number of patients with HIV-1 RNA levels below 50 copies/mL was 55.9% in the first month, 73.7% in the third month, 90.2% in the sixth month, and 100% in the ninth and 12th months. CONCLUSION: In our real-life observational study, BIC/FTC/TAF treatment achieved rapid viral suppression, maintained viral suppression in virally suppressed patients, and was effective for immunological recovery in both treatment-experienced and naive HIV patients. No serious side effects were observed. Our study has proved the potential of BIC/FTC/TAF as an important option in the treatment of HIV patients.
RESUMEN
Background: Rapid initiation of antiretroviral therapy (ART) reduces the transmission of HIV infection in the community. This study aimed to determine whether rapid ART initiation is effective compared to standard ART treatment in our country. Methods: Patients were grouped based on time to treatment initiation. HIV RNA levels, CD+4 T cell count, CD4/CD8 ratio, and ART regimens were recorded at baseline and follow-up visits for 12 months. Results: There were 368-ART naive adults (treatment initiated at the time of HIV diagnosis; 143 on the first day, 48 on the second-seventh day, and 177 after the seventh day). Although virological suppression rates at 12th months were higher in all groups, over 90% on average, there were no statistically significant differences in HIV-1 RNA suppression rates, CD+4 T cell count, and CD4/CD8 ratio normalization in the studied months but in multivariate logistic regression analysis; showed a significant correlation between both virological and immunological response and those with CD4+ T <350 cells/mL at 12th month in total patients. Conclusion: Our findings support the broader application of recommendations for rapid ART initiation in HIV patients.
RESUMEN
BACKGROUND: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. METHODS: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. RESULTS: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). CONCLUSION: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
Asunto(s)
Hepatitis C Crónica , Adulto , Anciano , Antivirales/efectos adversos , Quimioterapia Combinada , Hepacivirus/genética , Humanos , Masculino , Estudios Prospectivos , Ribavirina/uso terapéutico , Sofosbuvir/uso terapéutico , Respuesta Virológica Sostenida , Resultado del Tratamiento , TurquíaRESUMEN
BACKGROUND: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. METHODS: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. RESULTS: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). CONCLUSION: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization's objective of eliminating viral hepatitis.
Asunto(s)
Consumidores de Drogas , Hepatitis C Crónica , Hepatitis C , Abuso de Sustancias por Vía Intravenosa , Humanos , Hepatitis C Crónica/tratamiento farmacológico , Antivirales/uso terapéutico , Abuso de Sustancias por Vía Intravenosa/complicaciones , Abuso de Sustancias por Vía Intravenosa/tratamiento farmacológico , Estudios de Cohortes , Turquía/epidemiología , Estudios Prospectivos , Hepatitis C/tratamiento farmacológico , HepacivirusRESUMEN
Background: Exercise is believed to play an important role in maintaining functionality in patients with HIV and it is thought that researchers are increasingly interested in this field. We aimed to shed light on the historical development of research on HIV and exercise by utilizing visual mapping method. Methods: Overall, 1051 articles retrieved from Web of Science (WoS) core database were analyzed according to the publication year and language, number of issues, citation, country collaborations, co-citation networks and concept-topic trends by using CiteSpace software. Results: The United States played a key role in country collaborations, and had the highest citation burst. The most cited studies were meta-analysis studies. The studies gathered mainly around the clusters named "physical activity" and "metabolic abnormalities" meanwhile, the recent topics of research were heart failure, metabolism, comorbidity, Ethiopia, muscle, cardiovascular event and drug user. Conclusion: The reason why USA was found to be one of the key actors in the network is supposed to be the financial resources it can allocate for the studies conducted. It appears that the majority of the studies in the field dwell upon the impact of exercise on the physical parameters in HIV patients, whereas there are only a limited number of studies focusing on the impact of exercise on HIV-induced psychological and cognitive problems. Recent studies on neurocognitive impairment, on the other hand, are predictive of possible future popularity of such topics among researchers.
RESUMEN
Chronic inflammation that contributes to the deterioration of the mechanical form of both the vascular wall and the function of endothelial has been shown to cause vascular dysfunction in patients with human immunodeficiency virus (HIV). Nailfold videocapillaroscopy (NVC) is a noninvasive and simple technique used to analyze dermal microvasculature. The aims of our study were to detect the morphological and functional properties of microcirculation in HIV-positive patients utilizing NVC and to compare the results with those obtained from healthy individuals and investigate whether these changes had supported any correlation with HIV. In this prospective study, 51 male HIV-positive patients were the subjects and 59 male healthy individuals made up the control group. Capillaroscopic findings, obtained from both groups by NVC, were evaluated. Tortuosity, a capillaroscopic finding, was significantly higher in the group with HIV (p < .001). In logistic regression analysis, tortuosity [odds ratio (OR), 4.658; p = .001], bizarre capillary (OR, 1.733; p = .319), and capillary ectasia (OR, 0.867; p = .493) were considered significant. The changes of capillaroscopic findings were found to be correlated with HIV. We suggest videocapillaroscopy in the evaluation of microvascular changes in HIV patients, as a dependable contributing method.
Asunto(s)
Capilares/fisiopatología , Infecciones por VIH/diagnóstico , Microcirculación , Angioscopía Microscópica , Adulto , Anciano , Capilares/diagnóstico por imagen , Femenino , Infecciones por VIH/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Adulto JovenRESUMEN
In December 2019, cases of pneumonia were detected in Wuhan, China, which were caused by the highly contagious coronavirus. This study is aimed at comparing the confusion regarding the selection of effective diagnostic methods to make a mutual comparison among existing SARS-CoV-2 diagnostic tests and at determining the most effective one. Based on available published evidence and clinical practice, diagnostic tests of coronavirus disease (COVID-19) were evaluated by multi-criteria decision-making (MCDM) methods, namely, fuzzy preference ranking organization method for enrichment evaluation (fuzzy PROMETHEE) and fuzzy technique for order of preference by similarity to ideal solution (fuzzy TOPSIS). Computerized tomography of chest (chest CT), the detection of viral nucleic acid by polymerase chain reaction, cell culture, CoV-19 antigen detection, CoV-19 antibody IgM, CoV-19 antibody IgG, and chest X-ray were evaluated by linguistic fuzzy scale to compare among the diagnostic tests. This scale consists of selected parameters that possessed different weights which were determined by the experts' opinions of the field. The results of our study with both proposed MCDM methods indicated that the most effective diagnosis method of COVID-19 was chest CT. It is interesting to note that the methods that are consistently used in the diagnosis of viral diseases were ranked in second place for the diagnosis of COVID-19. However, each country should use appropriate diagnostic solutions according to its own resources. Our findings also show which diagnostic systems can be used in combination.
Asunto(s)
Técnicas de Laboratorio Clínico/métodos , Infecciones por Coronavirus/diagnóstico , Toma de Decisiones , Neumonía Viral/diagnóstico , Betacoronavirus , COVID-19 , Prueba de COVID-19 , Lógica Difusa , Humanos , Inmunoglobulina G , Modelos Estadísticos , Pandemias , Evaluación de Programas y Proyectos de Salud , Reproducibilidad de los Resultados , SARS-CoV-2 , Sensibilidad y Especificidad , Tomografía Computarizada por Rayos XRESUMEN
Background: Because of their similar modes of transmission, the simultaneous infection of viral hepatitis and human immunodeficiency virus are increasingly seen as a big problem related to human health. Aims: To determine the drug mutations in hepatitis B virus and/or hepatitis C virus co-infected human immunodeficiency virus-1 patients in Turkey. Study Design: Retrospective cross-sectional study. Methods: The present study was conducted between 2010 and 2017. HBsAg, anti-hepatitis C virus, and anti-human immunodeficiency virus were tested with ELISA. All anti-human immunodeficiency virus positive results by ELISA were verified for anti-human immunodeficiency virus positivity by a Western blot test, and Anti-human immunodeficiency virus positive patients with HBsAg and/or anti-hepatitis C virus positivity were included in the study. Subtyping and genotypic resistance analyses were performed by population sequencing of the viral protease and reverse transcriptase regions of the human immunodeficiency virus-1 pol gene. Results: We detected 3896 human immunodeficiency virus-1 positive patients whose sera were sent from numerous hospitals across the country to our polymerase chain reaction unit for detection of drug resistance mutations and whose molecular laboratory tests were completed. Viral hepatitis co-infections were detected in 4.3% (n=170) of patients. Hepatitis B virus and hepatitis C virus co-infection were observed in 3.2% and 0.5% of all human immunodeficiency virus-1 infected patients, respectively. The major human immunodeficiency virus-1 subtype detected was group M, subtype B (62.9%). However, 13.5% of drug resistance mutation motifs were found in human immunodeficiency virus-1 genomes of patients included in the study. Conclusion: Due to similar transmission routes, HIV1 patients are at risk of hepatitis B and C virus co-infection. However, antiretroviral drug resistance mutation model is similar to patients with hepatitis negative.
Asunto(s)
Coinfección/diagnóstico , Infecciones por VIH/diagnóstico , Hepatitis B/virología , Hepatitis C/virología , Coinfección/epidemiología , Coinfección/virología , Estudios Transversales , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Hepacivirus/patogenicidad , Hepatitis B/epidemiología , Hepatitis B/fisiopatología , Virus de la Hepatitis B/patogenicidad , Hepatitis C/epidemiología , Hepatitis C/fisiopatología , Humanos , Reacción en Cadena de la Polimerasa/métodos , Estudios Retrospectivos , Turquía/epidemiologíaRESUMEN
OBJECTIVES: The purpose of this study was to investigate dolutegravir (DTG) use among women and exposure to DTG during pregnancy in real world in Central and Eastern Europe and neighboring countries. MATERIAL AND METHODS: Centres from 20 countries included in the Euroguidelines in Central and Eastern Europe (ECEE) Network and Finland were asked to complete an on-line questionnaire. RESULTS: Seven centres from Czech Republic, Finland, Greece, Poland, Slovakia, and Turkey provided detailed information. DTG exposure was reported in 415 women, of which 26 were during pregnancy. Of those, 22 were on DTG at the time of conception and 4 had started DTG during pregnancy. Few women had conventional risk factors. The data on folic acid usage was unknown for eight women; 14 were using and four were not using folic acid. Four pregnancies were ongoing at the time of the study and of those with an outcome, 77.3% resulted with term, 13.6% preterm delivery, 4.5% spontaneous and 4.5% medical abortion. CONCLUSIONS: The DTG signal report indicates the importance of safety research for drug use in pregnancy and highlights the urgent need for systematic surveillance of pregnancy outcomes and neonatal surveillance. Countries with low- or moderate HIV prevalence should be included in studies reviewing pregnancy outcomes and in any surveillance system to ensure the accuracy of drug safety revision.